Literature DB >> 32183946

Chemotherapy and CDK4/6 Inhibition in Cancer Treatment: Timing Is Everything.

Anne Fassl1, Piotr Sicinski2.   

Abstract

Chemotherapy remains the main treatment option for patients with several tumor types. In this issue of Cancer Cell, Salvador-Barbero et al. demonstrate that treatment with CDK4/6 inhibitors after application of taxanes (or other chemotherapeutic compounds) strongly potentiates the anti-tumor effect due to repression of DNA repair machinery.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32183946     DOI: 10.1016/j.ccell.2020.02.007

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  5 in total

Review 1.  CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.

Authors:  Jordan L Kohlmeyer; David J Gordon; Munir R Tanas; Varun Monga; Rebecca D Dodd; Dawn E Quelle
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

2.  Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

Authors:  Shasha He; Xiaoling Fang; Xiaomeng Xia; Tao Hou; Tingting Zhang
Journal:  Oncol Rep       Date:  2020-09-01       Impact factor: 3.906

Review 3.  Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.

Authors:  Elizabeth R Smith; Marilyn Huang; Matthew P Schlumbrecht; Sophia H L George; Xiang-Xi Xu
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

4.  Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma.

Authors:  Zhichao Xue; Vivian Wai Yan Lui; Yongshu Li; Lin Jia; Chanping You; Xin Li; Wenying Piao; Hui Yuan; Pek Lan Khong; Kwok Wai Lo; Lydia Wai Ting Cheung; Victor Ho Fan Lee; Anne Wing Mui Lee; Sai Wah Tsao; Chi Man Tsang
Journal:  J Exp Clin Cancer Res       Date:  2020-11-26

Review 5.  Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.

Authors:  Jocelyn Y Hsu; Nathan D Seligson; John L Hays; Wayne O Miles; James L Chen
Journal:  JCO Precis Oncol       Date:  2022-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.